Reporting tumor genomic test results to SEER registries via linkages.

Autor:	Petkov VI; Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA., Byun JS; Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA., Ward KC; Emory University, Atlanta, GA, USA., Schussler NC; Information Management Services, Inc, Calverton, MD, USA., Archer NP; Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services, Austin, TX, USA., Bentler S; Iowa Cancer Registry, The University of Iowa, Iowa City, IA, USA., Doherty JA; Hunstman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA., Durbin EB; Cancer Research Informatics Shared Resource Facility, Markey Cancer Center, Kentucky Cancer Registry, University of Kentucky, Lexington, KY, USA., Gershman ST; Massachusetts Cancer Registry, Boston, MA, USA., Cheng I; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA., Insaf T; New York State Department of Health, New York State Cancer Registry, Albany, NY, USA., Gonsalves L; Connecticut Department of Public Health, Connecticut Tumor Registry, Hartford, CT, USA., Hernandez BY; University of Hawaii Cancer Center, Honolulu, HI, USA., Koch L; Illinois State Cancer Registry, Springfield, IL, USA., Liu L; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Monnereau A; Public Health Institute, Cancer Registry of Greater California, Sacramento, CA, USA., Morawski BM; Cancer Data Registry of Idaho, Boise, ID, USA., Schwartz SM; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA., Stroup A; New Jersey State Cancer Registry, Trenton, NJ, USA., Wiggins C; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA., Wu XC; School of Medicine, Louisiana State University, New Orleans, LA, USA., Bonds S; Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA., Negoita S; Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA., Penberthy L; Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Jazyk:	angličtina
Zdroj:	Journal of the National Cancer Institute. Monographs [J Natl Cancer Inst Monogr] 2024 Aug 01; Vol. 2024 (65), pp. 168-179.
DOI:	10.1093/jncimonographs/lgae013
Abstrakt:	Background: Precision medicine has become a mainstay of cancer care in recent years. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program has been an authoritative source of cancer statistics and data since 1973. However, tumor genomic information has not been adequately captured in the cancer surveillance data, which impedes population-based research on molecular subtypes. To address this, the SEER Program has developed and implemented a centralized process to link SEER registries' tumor cases with genomic test results that are provided by molecular laboratories to the registries. Methods: Data linkages were carried out following operating procedures for centralized linkages established by the SEER Program. The linkages used Match*Pro, a probabilistic linkage software, and were facilitated by the registries' trusted third party (an honest broker). The SEER registries provide to NCI limited datasets that undergo preliminary evaluation prior to their release to the research community. Results: Recently conducted genomic linkages included OncotypeDX Breast Recurrence Score, OncotypeDX Breast Ductal Carcinoma in Situ, OncotypeDX Genomic Prostate Score, Decipher Prostate Genomic Classifier, DecisionDX Uveal Melanoma, DecisionDX Preferentially Expressed Antigen in Melanoma, DecisionDX Melanoma, and germline tests results in Georgia and California SEER registries. Conclusions: The linkages of cancer cases from SEER registries with genomic test results obtained from molecular laboratories offer an effective approach for data collection in cancer surveillance. By providing de-identified data to the research community, the NCI's SEER Program enables scientists to investigate numerous research inquiries. (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu